MedTrace Logo

Multimodal Assesment of Alzheimer Patients

NCT06448403 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-08-07

No results posted yet for this study

Summary

The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD).

The main questions the study aims to answer are:

1. What findings can be used to earlier detect patients that will develop Alzheimers?
2. Which differences are seen between healthy and cognitively impaired patients?
3. Which differences are seen between patients with Alzheimers disease?

Participants will undergo:

* Cognitive tests
* Magnetic resonance imaging (MRI)
* Electroencephalography (EEG)
* Blood sample collection
* Fecal sample collection
* A randomized group will undergo polysomnography analysis.

Conditions

Interventions

BEHAVIORAL

Cognitive tests

Interview-based cognitive tests for assesment of cognitive levels.

DEVICE

MRI Scanning

MRI scanning with volumetric, resting and activity-based sequences.

DEVICE

64-channel EEG

EEG to quantifiy electric activity.

DEVICE

Polysomnography

A randomized group will undergo polysomnography.

BIOLOGICAL

Blood samples

Analysis of specific blood biomarkers.

BIOLOGICAL

Fecal samples

Analysis of bacterial composition.

Sponsors & Collaborators

  • Norwegian University of Science and Technology

    lead OTHER

Principal Investigators

  • Axel Sandvig, Prof., MD, PhD · Norwegian University of Science and Technology (NTNU) & St. Olavs Hospital, Trondheim University Hospital

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2030-12-29
Completion
2030-12-29

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06448403 on ClinicalTrials.gov